Search research articles
Contact Us
Filters
Showing results (141-150 of 196) with videos related to
Page
of 20
Sort By:
Journal of Parkinson'S Disease
|
May 22, 2023
Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease
Jennifer R Mammen, Rebecca M Speck, Glenn T Stebbins, et al.
Annals of Neurology
|
May 7, 2026
How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease
Tanya Simuni, Christopher S Coffey, Catherine M Kopil, et al.
JAMA Neurology
|
August 28, 2013
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease
Ju-Hee Kang, David J Irwin, Alice S Chen-Plotkin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 20, 2024
Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach
Connie Marras, Seyed-Mohammad Fereshtehnejad, Daniela Berg, et al.
Annals of Neurology
|
June 17, 2020
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
David J Irwin, Janel Fedler, Christopher S Coffey, et al.
Parkinsonism & Related Disorders
|
February 11, 2019
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
Neha Prakash, Chelsea Caspell-Garcia, Christopher Coffey, et al.
Movement Disorders Clinical Practice
|
June 19, 2023
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, et al.
NPJ Parkinson'S Disease
|
April 2, 2025
Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson's Disease
Jennifer R Mammen, Jamie L Adams, Rikki Mangrum, et al.
Journal of Parkinson'S Disease
|
December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
M Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Annals of Neurology
|
December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein Disease
Ethan G Brown, Lana M Chahine, Andrew Siderowf, et al.
Page
of 20
Search research articles
Search
Showing results (141-150 of 196) with videos related to
Sort By:
Page
of 20
Journal of Parkinson'S Disease
|
May 22, 2023
Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease
Jennifer R Mammen, Rebecca M Speck, Glenn T Stebbins, et al.
Annals of Neurology
|
May 7, 2026
How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease
Tanya Simuni, Christopher S Coffey, Catherine M Kopil, et al.
JAMA Neurology
|
August 28, 2013
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease
Ju-Hee Kang, David J Irwin, Alice S Chen-Plotkin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 20, 2024
Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach
Connie Marras, Seyed-Mohammad Fereshtehnejad, Daniela Berg, et al.
Annals of Neurology
|
June 17, 2020
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
David J Irwin, Janel Fedler, Christopher S Coffey, et al.
Parkinsonism & Related Disorders
|
February 11, 2019
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
Neha Prakash, Chelsea Caspell-Garcia, Christopher Coffey, et al.
Movement Disorders Clinical Practice
|
June 19, 2023
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, et al.
NPJ Parkinson'S Disease
|
April 2, 2025
Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson's Disease
Jennifer R Mammen, Jamie L Adams, Rikki Mangrum, et al.
Journal of Parkinson'S Disease
|
December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
M Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Annals of Neurology
|
December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein Disease
Ethan G Brown, Lana M Chahine, Andrew Siderowf, et al.
Page
of 20